Absence of dynamic neural oscillatory response to environmental conditions marks childhood attention deficit hyperactivity disorder / Anne B. ARNETT in Journal of Child Psychology and Psychiatry, 63-12 (December 2022)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 63-12 (December 2022) . - p.1615-1621 Titre : Absence of dynamic neural oscillatory response to environmental conditions marks childhood attention deficit hyperactivity disorder Type de document : texte imprimé Auteurs : Anne B. ARNETT, Auteur ; Margaret FEAREY, Auteur ; Virginia PEISCH, Auteur ; April R. LEVIN, Auteur Article en page(s) : p.1615-1621 Langues : Anglais (eng) Mots-clés : Child  Female  Humans  Male  Attention Deficit Disorder with Hyperactivity  Electroencephalography  Brain  Adhd  Eeg  cognition  neurodevelopmental disorders Index. décimale : PER Périodiques Résumé : BACKGROUND: Prior research suggests that symptoms of attention deficit hyperactivity disorder (ADHD) and related neurodevelopmental disorders may derive from alterations in the brain's ability to flexibly tune the balance between information integration and segregation and global versus local processing. This balance allows the brain to optimally filter salient stimuli in the environment and can be measured with electroencephalography (EEG) via calculation of the aperiodic spectral slope. A steeper aperiodic slope increases the capacity of global neural networks to process low-salience stimuli, while a flatter aperiodic slope reflects an emphasis on local neural networks that respond preferentially to high-salience input. Although aperiodic slope differences have been reported in ADHD, prior studies have not accounted for differing levels of stimulus input in experimental paradigms. There is evidence to suggest that dynamic shifts in neural oscillation patterns in response to changing environmental conditions could be critical for attention regulation. METHODS: Using high-density resting EEG, we measured aperiodic spectral slope during low contrast (lights off) and high contrast (lights on) environmental conditions in a sample of 88 7-11-year-old children diagnosed with ADHD and 29 controls (30% female). RESULTS: While controls showed a flatter aperiodic slope during the high contrast (lights on) as compared to low contrast (lights off) environmental condition, children with ADHD did not show any change in aperiodic slope across conditions. CONCLUSIONS: This study presents a novel etiological model of biological mechanisms associated with ADHD. Children with ADHD show suboptimal modulation of intrinsic neural activity in response to changing environmental input. The dynamic spectral slope is a promising candidate biomarker for ADHD. The possibility that dynamic spectral slope is associated with cognitive-behavioral regulation more broadly merits further investigation. En ligne : http://dx.doi.org/10.1111/jcpp.13645 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490 [article] Absence of dynamic neural oscillatory response to environmental conditions marks childhood attention deficit hyperactivity disorder [texte imprimé] / Anne B. ARNETT, Auteur ; Margaret FEAREY, Auteur ; Virginia PEISCH, Auteur ; April R. LEVIN, Auteur . - p.1615-1621. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 63-12 (December 2022) . - p.1615-1621 Mots-clés : Child  Female  Humans  Male  Attention Deficit Disorder with Hyperactivity  Electroencephalography  Brain  Adhd  Eeg  cognition  neurodevelopmental disorders Index. décimale : PER Périodiques Résumé : BACKGROUND: Prior research suggests that symptoms of attention deficit hyperactivity disorder (ADHD) and related neurodevelopmental disorders may derive from alterations in the brain's ability to flexibly tune the balance between information integration and segregation and global versus local processing. This balance allows the brain to optimally filter salient stimuli in the environment and can be measured with electroencephalography (EEG) via calculation of the aperiodic spectral slope. A steeper aperiodic slope increases the capacity of global neural networks to process low-salience stimuli, while a flatter aperiodic slope reflects an emphasis on local neural networks that respond preferentially to high-salience input. Although aperiodic slope differences have been reported in ADHD, prior studies have not accounted for differing levels of stimulus input in experimental paradigms. There is evidence to suggest that dynamic shifts in neural oscillation patterns in response to changing environmental conditions could be critical for attention regulation. METHODS: Using high-density resting EEG, we measured aperiodic spectral slope during low contrast (lights off) and high contrast (lights on) environmental conditions in a sample of 88 7-11-year-old children diagnosed with ADHD and 29 controls (30% female). RESULTS: While controls showed a flatter aperiodic slope during the high contrast (lights on) as compared to low contrast (lights off) environmental condition, children with ADHD did not show any change in aperiodic slope across conditions. CONCLUSIONS: This study presents a novel etiological model of biological mechanisms associated with ADHD. Children with ADHD show suboptimal modulation of intrinsic neural activity in response to changing environmental input. The dynamic spectral slope is a promising candidate biomarker for ADHD. The possibility that dynamic spectral slope is associated with cognitive-behavioral regulation more broadly merits further investigation. En ligne : http://dx.doi.org/10.1111/jcpp.13645 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490

Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials / Logan SHURTZ in Autism, 27-4 (May 2023)  

Public ISBD [article]  inAutism > 27-4 (May 2023) . - p.952-966 Titre : Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials Type de document : texte imprimé Auteurs : Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C. MCPARTLAND, Auteur ; April R. LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M. KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J. WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A. BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A. SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S. JESTE, Auteur Article en page(s) : p.952-966 Langues : Anglais (eng) Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499 [article] Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials [texte imprimé] / Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C. MCPARTLAND, Auteur ; April R. LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M. KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J. WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A. BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A. SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S. JESTE, Auteur . - p.952-966. Langues : Anglais (eng) in Autism > 27-4 (May 2023) . - p.952-966 Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499

EEG power at 3 months in infants at high familial risk for autism / April R. LEVIN in Journal of Neurodevelopmental Disorders, 9-1 (December 2017)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 9-1 (December 2017) . - p.34 Titre : EEG power at 3 months in infants at high familial risk for autism Type de document : texte imprimé Auteurs : April R. LEVIN, Auteur ; Kandice J. VARCIN, Auteur ; Heather M. O'LEARY, Auteur ; Helen TAGER-FLUSBERG, Auteur ; Charles A. NELSON, Auteur Article en page(s) : p.34 Langues : Anglais (eng) Mots-clés : Autism  Biomarker  Early development  Electroencephalography  Infant siblings Index. décimale : PER Périodiques Résumé : BACKGROUND: Alterations in brain development during infancy may precede the behavioral manifestation of developmental disorders. Infants at increased risk for autism are also at increased risk for other developmental disorders, including, quite commonly, language disorders. Here we assess the extent to which electroencephalographic (EEG) differences in infants at high versus low familial risk for autism are present by 3 months of age, and elucidate the functional significance of EEG power at 3 months in predicting later development. METHODS: EEG data were acquired at 3 months in infant siblings of children with autism (high risk; n = 29) and infant siblings of typically developing children (low risk; n = 19) as part of a prospective, longitudinal investigation. Development across multiple domains was assessed at 6, 9, 12, 18, 24, and 36 months. Diagnosis of autism was determined at 18-36 months. We assessed relationships between 3-month-olds' frontal EEG power and autism risk, autism outcome, language development, and development in other domains. RESULTS: Infants at high familial risk for autism had reduced frontal power at 3 months compared to infants at low familial risk for autism, across several frequency bands. Reduced frontal high-alpha power at 3 months was robustly associated with poorer expressive language at 12 months. CONCLUSIONS: Reduced frontal power at 3 months may indicate increased risk for reduced expressive language skills at 12 months. This finding aligns with prior studies suggesting reduced power is a marker for atypical brain function, and infants at familial risk for autism are also at increased risk for altered developmental functioning in non-autism-specific domains. En ligne : http://dx.doi.org/10.1186/s11689-017-9214-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=350 [article] EEG power at 3 months in infants at high familial risk for autism [texte imprimé] / April R. LEVIN, Auteur ; Kandice J. VARCIN, Auteur ; Heather M. O'LEARY, Auteur ; Helen TAGER-FLUSBERG, Auteur ; Charles A. NELSON, Auteur . - p.34. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 9-1 (December 2017) . - p.34 Mots-clés : Autism  Biomarker  Early development  Electroencephalography  Infant siblings Index. décimale : PER Périodiques Résumé : BACKGROUND: Alterations in brain development during infancy may precede the behavioral manifestation of developmental disorders. Infants at increased risk for autism are also at increased risk for other developmental disorders, including, quite commonly, language disorders. Here we assess the extent to which electroencephalographic (EEG) differences in infants at high versus low familial risk for autism are present by 3 months of age, and elucidate the functional significance of EEG power at 3 months in predicting later development. METHODS: EEG data were acquired at 3 months in infant siblings of children with autism (high risk; n = 29) and infant siblings of typically developing children (low risk; n = 19) as part of a prospective, longitudinal investigation. Development across multiple domains was assessed at 6, 9, 12, 18, 24, and 36 months. Diagnosis of autism was determined at 18-36 months. We assessed relationships between 3-month-olds' frontal EEG power and autism risk, autism outcome, language development, and development in other domains. RESULTS: Infants at high familial risk for autism had reduced frontal power at 3 months compared to infants at low familial risk for autism, across several frequency bands. Reduced frontal high-alpha power at 3 months was robustly associated with poorer expressive language at 12 months. CONCLUSIONS: Reduced frontal power at 3 months may indicate increased risk for reduced expressive language skills at 12 months. This finding aligns with prior studies suggesting reduced power is a marker for atypical brain function, and infants at familial risk for autism are also at increased risk for altered developmental functioning in non-autism-specific domains. En ligne : http://dx.doi.org/10.1186/s11689-017-9214-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=350

Electroencephalographic spectral power as a marker of cortical function and disease severity in girls with Rett syndrome / Katherine J. ROCHE in Journal of Neurodevelopmental Disorders, 11-1 (December 2019)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 11-1 (December 2019) . - 15 p. Titre : Electroencephalographic spectral power as a marker of cortical function and disease severity in girls with Rett syndrome Type de document : texte imprimé Auteurs : Katherine J. ROCHE, Auteur ; Jocelyn J. LEBLANC, Auteur ; April R. LEVIN, Auteur ; Heather M. O'LEARY, Auteur ; Lauren M. BACZEWSKI, Auteur ; Charles A. NELSON, Auteur Article en page(s) : 15 p. Langues : Anglais (eng) Mots-clés : Biomarker  Eeg  Electroencephalography  Electrophysiology  Rett syndrome  Spectral power Index. décimale : PER Périodiques Résumé : BACKGROUND: Rett syndrome is a neurodevelopmental disorder caused by a mutation in the X-linked MECP2 gene. Individuals with Rett syndrome typically develop normally until around 18 months of age before undergoing a developmental regression, and the disorder can lead to cognitive, motor, sensory, and autonomic dysfunction. Understanding the mechanism of developmental regression represents a unique challenge when viewed through a neuroscience lens. Are circuits that were previously established erased, and are new ones built to supplant old ones? One way to examine circuit-level changes is with the use of electroencephalography (EEG). Previous studies of the EEG in individuals with Rett syndrome have focused on morphological characteristics, but few have explored spectral power, including power as an index of brain function or disease severity. This study sought to determine if EEG power differs in girls with Rett syndrome and typically developing girls and among girls with Rett syndrome based on various clinical characteristics in order to better understand neural connectivity and cortical organization in individuals with this disorder. METHODS: Resting state EEG data were acquired from girls with Rett syndrome (n = 57) and typically developing children without Rett syndrome (n = 37). Clinical data were also collected for girls with Rett syndrome. EEG power across several brain regions in numerous frequency bands was then compared between girls with Rett syndrome and typically developing children and power in girls with Rett syndrome was compared based on these clinical measures. 1/f slope was also compared between groups. RESULTS: Girls with Rett syndrome demonstrate significantly lower power in the middle frequency bands across multiple brain regions. Additionally, girls with Rett syndrome that are postregression demonstrate significantly higher power in the lower frequency delta and theta bands and a significantly more negative slope of the power spectrum. Increased power in these bands, as well as a more negative 1/f slope, trended with lower cognitive assessment scores. CONCLUSIONS: Increased power in lower frequency bands is consistent with previous studies demonstrating a "slowing" of the background EEG in Rett syndrome. This increase, particularly in the delta band, could represent abnormal cortical inhibition due to dysfunctional GABAergic signaling and could potentially be used as a marker of severity due to associations with more severe Rett syndrome phenotypes. En ligne : https://dx.doi.org/10.1186/s11689-019-9275-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=409 [article] Electroencephalographic spectral power as a marker of cortical function and disease severity in girls with Rett syndrome [texte imprimé] / Katherine J. ROCHE, Auteur ; Jocelyn J. LEBLANC, Auteur ; April R. LEVIN, Auteur ; Heather M. O'LEARY, Auteur ; Lauren M. BACZEWSKI, Auteur ; Charles A. NELSON, Auteur . - 15 p. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 11-1 (December 2019) . - 15 p. Mots-clés : Biomarker  Eeg  Electroencephalography  Electrophysiology  Rett syndrome  Spectral power Index. décimale : PER Périodiques Résumé : BACKGROUND: Rett syndrome is a neurodevelopmental disorder caused by a mutation in the X-linked MECP2 gene. Individuals with Rett syndrome typically develop normally until around 18 months of age before undergoing a developmental regression, and the disorder can lead to cognitive, motor, sensory, and autonomic dysfunction. Understanding the mechanism of developmental regression represents a unique challenge when viewed through a neuroscience lens. Are circuits that were previously established erased, and are new ones built to supplant old ones? One way to examine circuit-level changes is with the use of electroencephalography (EEG). Previous studies of the EEG in individuals with Rett syndrome have focused on morphological characteristics, but few have explored spectral power, including power as an index of brain function or disease severity. This study sought to determine if EEG power differs in girls with Rett syndrome and typically developing girls and among girls with Rett syndrome based on various clinical characteristics in order to better understand neural connectivity and cortical organization in individuals with this disorder. METHODS: Resting state EEG data were acquired from girls with Rett syndrome (n = 57) and typically developing children without Rett syndrome (n = 37). Clinical data were also collected for girls with Rett syndrome. EEG power across several brain regions in numerous frequency bands was then compared between girls with Rett syndrome and typically developing children and power in girls with Rett syndrome was compared based on these clinical measures. 1/f slope was also compared between groups. RESULTS: Girls with Rett syndrome demonstrate significantly lower power in the middle frequency bands across multiple brain regions. Additionally, girls with Rett syndrome that are postregression demonstrate significantly higher power in the lower frequency delta and theta bands and a significantly more negative slope of the power spectrum. Increased power in these bands, as well as a more negative 1/f slope, trended with lower cognitive assessment scores. CONCLUSIONS: Increased power in lower frequency bands is consistent with previous studies demonstrating a "slowing" of the background EEG in Rett syndrome. This increase, particularly in the delta band, could represent abnormal cortical inhibition due to dysfunctional GABAergic signaling and could potentially be used as a marker of severity due to associations with more severe Rett syndrome phenotypes. En ligne : https://dx.doi.org/10.1186/s11689-019-9275-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=409

Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials / Susan FAJA in Autism Research, 16-5 (May 2023)  

Public ISBD [article]  inAutism Research > 16-5 (May 2023) . - p.981-996 Titre : Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials Type de document : texte imprimé Auteurs : Susan FAJA, Auteur ; Maura SABATOS-DEVITO, Auteur ; Aksheya SRIDHAR, Auteur ; Jocelyn KUHN, Auteur ; Julia I. NIKOLAEVA, Auteur ; Catherine A. SUGAR, Auteur ; Sara Jane WEBB, Auteur ; Raphael A. BERNIER, Auteur ; Linmarie SIKICH, Auteur ; Gerhard HELLEMANN, Auteur ; Damla SENTURK, Auteur ; Adam J. NAPLES, Auteur ; Frederick SHIC, Auteur ; April R. LEVIN, Auteur ; Helen A. SEOW, Auteur ; James DZIURA, Auteur ; Shafali S. JESTE, Auteur ; Katarzyna CHAWARSKA, Auteur ; Charles A. NELSON, Auteur ; Geraldine DAWSON, Auteur ; James C. MCPARTLAND, Auteur ; THE AUTISM BIOMARKERS CONSORTIUM FOR CLINICAL TRIALS, Auteur Article en page(s) : p.981-996 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Abstract Clinical trials in autism spectrum disorder (ASD) often rely on clinician rating scales and parent surveys to measure autism-related features and social behaviors. To aid in the selection of these assessments for future clinical trials, the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) directly compared eight common instruments with respect to acquisition rates, sensitivity to group differences, equivalence across demographic sub-groups, convergent validity, and stability over a 6-week period. The sample included 280 children diagnosed with ASD (65 girls) and 119 neurotypical children (36 girls) aged from 6 to 11 years. Full scale IQ for ASD ranged from 60 to 150 and for neurotypical ranged from 86 to 150. Instruments measured clinician global assessment and autism-related behaviors, social communication abilities, adaptive function, and social withdrawal behavior. For each instrument, we examined only the scales that measured social or communication functioning. Data acquisition rates were at least 97.5% at T1 and 95.7% at T2. All scales distinguished diagnostic groups. Some scales significantly differed by participant and/or family demographic characteristics. Within the ASD group, most clinical instruments exhibited weak (? |0.1|) to moderate (? |0.4|) intercorrelations. Short-term stability was moderate (ICC: 0.5-0.75) to excellent (ICC: >0.9) within the ASD group. Variations in the degree of stability may inform viability for different contexts of use, such as identifying clinical subgroups for trials versus serving as a modifiable clinical outcome. All instruments were evaluated in terms of their advantages and potential concerns for use in clinical trials. En ligne : http://dx.doi.org/https://doi.org/10.1002/aur.2905 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=503 [article] Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials [texte imprimé] / Susan FAJA, Auteur ; Maura SABATOS-DEVITO, Auteur ; Aksheya SRIDHAR, Auteur ; Jocelyn KUHN, Auteur ; Julia I. NIKOLAEVA, Auteur ; Catherine A. SUGAR, Auteur ; Sara Jane WEBB, Auteur ; Raphael A. BERNIER, Auteur ; Linmarie SIKICH, Auteur ; Gerhard HELLEMANN, Auteur ; Damla SENTURK, Auteur ; Adam J. NAPLES, Auteur ; Frederick SHIC, Auteur ; April R. LEVIN, Auteur ; Helen A. SEOW, Auteur ; James DZIURA, Auteur ; Shafali S. JESTE, Auteur ; Katarzyna CHAWARSKA, Auteur ; Charles A. NELSON, Auteur ; Geraldine DAWSON, Auteur ; James C. MCPARTLAND, Auteur ; THE AUTISM BIOMARKERS CONSORTIUM FOR CLINICAL TRIALS, Auteur . - p.981-996. Langues : Anglais (eng) in Autism Research > 16-5 (May 2023) . - p.981-996 Index. décimale : PER Périodiques Résumé : Abstract Clinical trials in autism spectrum disorder (ASD) often rely on clinician rating scales and parent surveys to measure autism-related features and social behaviors. To aid in the selection of these assessments for future clinical trials, the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) directly compared eight common instruments with respect to acquisition rates, sensitivity to group differences, equivalence across demographic sub-groups, convergent validity, and stability over a 6-week period. The sample included 280 children diagnosed with ASD (65 girls) and 119 neurotypical children (36 girls) aged from 6 to 11 years. Full scale IQ for ASD ranged from 60 to 150 and for neurotypical ranged from 86 to 150. Instruments measured clinician global assessment and autism-related behaviors, social communication abilities, adaptive function, and social withdrawal behavior. For each instrument, we examined only the scales that measured social or communication functioning. Data acquisition rates were at least 97.5% at T1 and 95.7% at T2. All scales distinguished diagnostic groups. Some scales significantly differed by participant and/or family demographic characteristics. Within the ASD group, most clinical instruments exhibited weak (? |0.1|) to moderate (? |0.4|) intercorrelations. Short-term stability was moderate (ICC: 0.5-0.75) to excellent (ICC: >0.9) within the ASD group. Variations in the degree of stability may inform viability for different contexts of use, such as identifying clinical subgroups for trials versus serving as a modifiable clinical outcome. All instruments were evaluated in terms of their advantages and potential concerns for use in clinical trials. En ligne : http://dx.doi.org/https://doi.org/10.1002/aur.2905 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=503

Parental Language Input Predicts Neuroscillatory Patterns Associated with Language Development in Toddlers at Risk of Autism / Rachel R. ROMEO in Journal of Autism and Developmental Disorders, 52-6 (June 2022)  

Permalink

Phenotypic variation in neural sensory processing by deletion size, age, and sex in Phelan-McDermid syndrome / Melody Reese SMITH in Journal of Neurodevelopmental Disorders, 17 (2025)  

Permalink

Reduced frontal gamma power at 24 months is associated with better expressive language in toddlers at risk for autism / Carol L. WILKINSON in Autism Research, 12-8 (August 2019)  

Permalink

Shifted phase of EEG cross-frequency coupling in individuals with Phelan-McDermid syndrome / Michael G. MARISCAL in Molecular Autism, 12 (2021)  

Permalink

The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials / Frederick SHIC in Molecular Autism, 13 (2022)  

Permalink

---

1 (1 - 10 / 10) Par page : 25 50 100 200